A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers

Author： Hosseinzadeh Sahar  

Publisher： Informa Healthcare

ISSN： 1521-0464

Source： Drug Delivery, Vol.20, Iss.3-4, 2013-04, pp. : 190-198

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen

By Bolhassani Azam   Ghasemi Nahid   Servis Catherine   Taghikhani Mohammad   Rafati Sima  

Drug Delivery, Vol. 16, Iss. 4, 2009-05 ,pp. : 196-204

Informa Healthcare

Access to resources Recommend Favorite

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine: For the Prevention of Genital Warts in Males

By Garnock-Jones Karly P.  

Drugs, Vol. 71, Iss. 5, 2011-03 ,pp. : 591-602

Adis International

Access to resources Recommend Favorite

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males†: Profile Report

By Garnock-Jones Karly P.  

Drugs in R&D, Vol. 12, Iss. 4, 2012-12 ,pp. : 235-238

Adis International

Access to resources Recommend Favorite

HPV-16 vaccine reduces incidence of HPV infections and cervical neoplasia

By  

Inpharma, Vol. 1, Iss. 1366, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

HPV vaccine delivery strategy depends on country

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 659, 2012-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite